GET DAILY SIGNALSUnitedHealth Group (UNH): Can Shares Reach the $490 Target?
Key Takeaways
- The central $490 stock price target is the arithmetic mean of nine verified, current analyst price targets reviewed for this article, rounded from a calculated average of roughly $493.
- At the latest verified close near $410.91, reaching $490 implies roughly 19% upside from current levels.
- Individual analyst price targets range from a low of $438 (Deutsche Bank) to a high of $531 (Morgan Stanley), reflecting a meaningful spread in views.
- The strongest supports are better-than-expected third-quarter results, a third full-year guidance increase, and improving medical cost trends.
- The biggest risks are Medicare Advantage regulation, residual Department of Justice scrutiny, and a valuation that has already re-rated higher.
- Readers can find more on Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
- Explore Trending AI Robots to see how AI-driven strategies are monitoring opportunities across the market.
Analyst Price Targets and Consensus View
This analysis draws from nine current, individually verified analyst price targets published in mid-to-late October 2026, following UnitedHealth's third-quarter earnings report. The targets range from Deutsche Bank's $438 to Morgan Stanley's $531, with most other firms clustered between $487 and $524. The simple arithmetic mean of these nine targets is approximately $493, which rounds to the $490 central target used throughout this article.
Views differ more than the headline average suggests. Morgan Stanley ($531), J.P. Morgan ($524), Goldman Sachs ($506), Piper Sandler ($504), Mizuho ($500), and RBC Capital ($498) sit at or above $500, while Wells Fargo ($487), Jefferies ($453), and Deutsche Bank ($438) are more restrained. Notably, some firms trimmed targets even while keeping buy ratings — Wells Fargo lowered its target to $487 from $526 — while Deutsche Bank carries a Hold rating, arguing the near-term valuation already prices in much of the expected recovery. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Bullish analysts point to a multi-year, multi-segment margin recovery and durable double-digit earnings growth, while the more cautious voices focus on valuation and residual policy uncertainty. The analyst consensus on UNH is best described as moderately bullish but not uniform.
Current Market Position and Path Toward the Target
At the latest verified close of $410.91, UNH trades roughly 19% below the $490 central target — a substantial, though not extreme, move. The shares have already climbed far off their 52-week low of $255.97 and now sit within reach of the 52-week high near $461.62.
The path toward the target runs through improving fundamentals. After a period defined by elevated Medicare Advantage medical costs and a Department of Justice investigation, UnitedHealth reported third-quarter adjusted EPS of $4.69, well above consensus near $4.14, on a better-than-expected MLR. Management raised 2026 adjusted EPS guidance for the third time this year, with the floor now implying roughly 25% year-over-year growth, and described OptumHealth's outperformance as durable.
What Could Support a Move Toward the Target
- Earnings momentum. A clean third-quarter beat and repeated guidance increases give analysts a credible basis for higher targets.
- Improving cost trends. A better MLR and management's pricing discipline in Medicare Advantage support the margin-recovery thesis.
- Optum and value-based care. Continued strength in the higher-growth Optum business underpins the long-term growth argument.
- Positive analyst revisions. Several firms raised targets in October, with the central target now well above current trading levels.
What Could Prevent the Target From Being Reached
- Valuation. After a sharp rally, some analysts argue the forward multiple already discounts the expected 2027–2028 earnings recovery.
- Regulatory risk. Medicare Advantage rate and policy decisions can quickly reshape margin assumptions across managed care.
- Legal scrutiny. The Department of Justice investigation into Medicare billing practices remains an unresolved overhang.
- Diverging targets. The wide $438-to-$531 range signals genuine disagreement about how durable the margin recovery will be.
Technical Levels and Market Structure
The 52-week high near $461.62 is the nearest major technical hurdle; a sustained move above it would open a path toward the $490 area. On the downside, the psychological $400 level and the prior consolidation zone near $390 represent support areas to watch. UNH's longer-term structure has shifted from a deep decline to a recovery, but the stock remains below its historical highs.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms vary. Investors should monitor quarterly earnings and MLR trends, any further guidance revisions, Medicare Advantage rate notices, and developments in the Department of Justice investigation. Changes in analyst price targets and ratings will also signal whether the recovery thesis is gaining or losing traction.
Final Assessment
The $490 central target for UNH is the average of nine verified analyst price targets ranging from $438 to $531, and it sits roughly 19% above the latest verified price near $410.91. Reaching it would require the margin-recovery story to keep delivering — sustained MLR improvement, continued guidance increases, and durable Optum growth — while avoiding fresh regulatory or legal setbacks. The wide analyst range and a handful of recently lowered targets underscore that the outcome is far from certain. Investors should watch earnings, Medicare Advantage policy, the Department of Justice investigation, and analyst revisions before drawing conclusions about whether the target is achievable.
Exploring AI Daily Buy/Sell Signals for UNH
In my own analysis, I frequently turn to Tickeron’s AI Daily Buy/Sell Signals to stay on top of shifting conditions in stocks like UNH. These signals draw on artificial intelligence to scan thousands of securities in real time, combining technical patterns and market data to highlight potential entry or exit points. For healthcare names in particular, the tool helps cut through noise and focus on actionable changes as earnings, costs, and policy developments unfold.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
UNH saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for UNH moved out of overbought territory on October 28, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 61 similar instances where the indicator exited the overbought zone. In 40 of the 61 cases the stock moved lower. This puts the odds of a downward move at 66%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for UNH moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 19 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.
UNH broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 09, 2026. You may want to consider a long position or call options on UNH as a result. In 50 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.
The Moving Average Convergence Divergence (MACD) for UNH just turned positive on October 05, 2026. Looking at past instances where UNH's MACD turned positive, the stock continued to rise in 26 of 45 cases over the following month. The odds of a continued upward trend are 58%.
UNH moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for UNH crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.
Following a +4.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNH advanced for three days, in 182 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 116 of 245 cases where UNH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 47%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating fairly steady price growth. UNH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.711) is normal, around the industry mean (3.380). P/E Ratio (26.088) is within average values for comparable stocks, (124.266). Projected Growth (PEG Ratio) (1.025) is also within normal values, averaging (0.786). UNH has a moderately high Dividend Yield (0.023) as compared to the industry average of (0.009). P/S Ratio (0.757) is also within normal values, averaging (0.569).
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of hospital and medical service plans
Industry ManagedHealthCare
Advertisement